1. Scrip
  2. >>Therapy Areas

Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner

 
• By Eleanor Malone

Takeda's $50m+ deal for Enterome's EB8018 is based on a separate platform from that being used under the French company's collaboration with Johnson & Johnson.

Intestine
Crohn's disease in the intestine • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. has agreed a second deal with French firm Enterome SA, which focuses on developing drugs based on understanding the behavior of the human gut microbiome. Takeda will pay $50m up front to collaborate on developing and marketing EB8018, an orally active, gut-restricted small-molecule drug aimed at a novel target in Crohn's disease.

The deal helps Takeda expand its R&D pipeline in a franchise in which it is traditionally strong (sales of its top-selling drug, Entyvio (vedolizumab) for Crohn's and ulcerative colitis, were ¥201bn ($1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.